CRBU Earnings & Financial Statements
Caribou Biosciences, Inc.
$0.62
-$0.52(-45.60%)
48
Overall
60
Value
45
Tech
39
Quality
Market Cap
$121.68M
Volume
37.29M
52W Range
$1.22 - $3.54
Target Price
$11.86
CRBU earnings and financial statements: Caribou Biosciences, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
CRBU Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $11.16M | $9.99M | $34.48M | $13.85M | $9.60M |
| Operating income | -$148.34M | -$166.62M | -$116.06M | -$106.40M | -$66.98M |
| EBITDA | -$145.03M | -$145.19M | -$98.35M | -$104.78M | -$65.57M |
| Net income | -$148.13M | -$149.10M | -$102.07M | -$99.42M | -$66.92M |
| EPS (diluted) | $-1.59 | $-1.65 | $-1.38 | $-1.64 | $-2.11 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $175.37M | $313.31M | $432.21M | $373.76M | $442.36M |
| Total liabilities | $53.19M | $60.36M | $63.81M | $72.89M | $54.53M |
| Shareholders’ equity | $122.17M | $252.95M | $368.40M | $300.87M | $387.82M |
| Cash and equivalents | $12.36M | $16.29M | $51.16M | $58.34M | $240.42M |
| Long-term debt | $26.03M | $25.06M | $25.91M | $26.78M | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$111.00M | -$138.20M | -$93.29M | -$90.97M | -$32.52M |
| Capital expenditure | -$1.36M | -$4.87M | -$11.61M | -$7.05M | -$3.12M |
| Free cash flow | -$112.36M | -$143.08M | -$104.90M | -$98.02M | -$35.64M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CRBU | $0.62 | -45.6% | 37.29M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Caribou Biosciences, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW